Navigation Links
Pharmacyclics to Host Webcast and Conference Call to Discuss Clinical Updates on Its HDAC and BTK Program as Presented at The American Society of Hematology Meeting Dec. 6 & 7
Date:12/3/2009

SUNNYVALE, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of immune mediated diseases and cancer, today announced that it will host a webcast and conference call on, Tuesday, December 8, 2009 at 11:00am Eastern Time (10:00am Central Time and 8:00am Pacific Time) to discuss clinical data regarding its HDAC Program (PCI-24781) and its BTK Program (PCI-32765) that will be presented at the American Society of Hematology (ASH) meeting.


Date: December 8, 2009
Time: 11:00AM ET (10:00AM CT and 8:00AM PT)

Listen via Internet: http://ir.pharmacyclics.com/events.cfm

Toll-free: (877) 700-2945
International: (706) 643-1591
Conference ID: 45071660

A webcast replay will be available on the Pharmacyclics website for 30 days.

The following Posters will be presented at ASH:

Title: Phase I Analysis of the Safety and Pharmacodynamics of the Novel Broad Spectrum Histone Deacetylase Inhibitor (HDACi) PCI-24781 in Relapsed and Refractory Lymphoma


Date / Time:  Sunday, December 6, 2009, 6:00PM-8:00PM
Location:  Hall E (Ernest N. Morial Convention Center) Poster Board II-702
Poster Session: Lymphoma: Therapy with Biologic Agents, excluding Pre-
 Clinical Models Poster II
Primary presenter: Dr. Andrew Evens, Northwestern University

Title: A Phase I Dose Escalation Study of the Btk Inhibitor PCI-32765 in Relapsed and Refractory B Cell Non-Hodgkin Lymphoma and Use of a Novel Fluorescent Probe Pharmacodynamic Assay


Date / Time:  Monday, December 7, 2009, 6:00PM-8:00PM
Location:  Hall E (Ernest N. Morial Convention Center) Poster Board
 III-649
Poster Session: Lymphoma: Chemotherapy, excluding Pre-Clinical Models
 Poster III
Primary presenter: Dr. Daniel Pollyea, Stanford University

About Pharmacyclics

Pharmacyclics® is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative small-molecule drugs for the treatment of immune mediated disease and cancer. The purpose of the company is to create a profitable business by generating income from products it develops, licenses and commercializes, either with one or several potential partners or alone as may best forward the economic interest of its stakeholders. The Company endeavors to create novel, patentable, differentiated products that have the potential to significantly improve the standard of care in the markets it serves. Presently, Pharmacyclics has four product candidates in clinical development and two product candidates in pre-clinical development. It is Pharmacyclics' business strategy to establish collaborations with large pharmaceutical and biotechnology companies for the purpose of generating present and future income in exchange for adding to their product pipelines. Pharmacyclics strives to generate collaborations that allow it to retain valuable territorial rights and simultaneously fast forward the clinical development and commercialization of its products. The Company is headquartered in Sunnyvale, California and is listed on NASDAQ under the symbol PCYC. To learn more about how Pharmacyclics advances science to improve human healthcare visit us at http://www.pharmacyclics.com.


Contact:
Ramses Erdtmann
Vice President of Finance
Phone: 408-215-3325

SOURCE Pharmacyclics, Inc.


'/>"/>
SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
2. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
3. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
4. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
5. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
8. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
9. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
10. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
11. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/16/2017)...  Northern Colorado,s newest tattoo removal clinic, The ... Loveland featuring the Astanza Duality ... of unwanted tattoos and delivers complete tattoo removal, selective ... "Tattoos are beautiful forms of self-expression, however, not all ... said Johnny Trzasko , owner. "The Ink Shrinks ...
(Date:1/16/2017)... and PUNE, India , January 16, 2017 /PRNewswire/ ... titled, "Antioxidants Market by Type - Global Opportunity Analysis and Industry Forecast, 2014 ... expected to reach $4,531 million by 2022, registering a CAGR of 6.42% during ... more than one-third share of the global volume in 2015. ... ...
(Date:1/16/2017)... January 16, 2017 Bill is an internationally ... general management and leadership positions with global medical device companies, including ... track record of launching new products and building successful businesses in ... Africa and North America ... Educated at ...
Breaking Medicine Technology:
(Date:1/16/2017)... ... January 16, 2017 , ... ... partnership with an innovator in the wheelchair accessibility industry, BraunAbility . Incentive ... salespeople to sell wheelchair accessible vehicles. With this new incentive plan, BraunAbility plans ...
(Date:1/16/2017)... ... January 16, 2017 , ... In 1985, the International ... training standards to an international multidisciplinary group of healthcare treatment providers and helping ... to further its mission at the grassroots level, iaedp launched MemberSHARE, an online ...
(Date:1/16/2017)... ... January 16, 2017 , ... NexTec Group has been selected as a ... honored for their accomplishments in the field of midmarket financial software. , Members of ... and innovation. Selection is not based on revenue and those firms chosen represent a ...
(Date:1/15/2017)... (PRWEB) , ... January 15, 2017 , ... ... that Albertsons Companies has achieved accreditation for its specialty care services. Albertsons ... its own in-house specialty care service for pharmacy patients. , Accreditation by ACHC ...
(Date:1/15/2017)... ... January 15, 2017 , ... The Gravity Vault Indoor Rock Climbing ... As construction wraps up on the 14,000+ square foot climbing gym, the owners anticipate ... including three in New Jersey and two in New York. With this being its ...
Breaking Medicine News(10 mins):